INTRODUCTION {#S5}
============

Severe obesity has long been recognized to increase cardiovascular disease (CVD) risk in adults and adolescents ([@R1]--[@R3]). Poor cardiovascular health is strongly associated with obesity ([@R4]) and cardiovascular health has been demonstrated to decrease with obesity severity ([@R4], [@R5]). The prevalence of severe obesity in childhood and adolescence, defined as ≥120% of the 95^th^ percentile of BMI for sex and age, continues to rise and now impacts millions of youth ([@R6]). Obesity in adolescence tracks into adulthood, increasing the risk of cardio-metabolic morbidity 15-fold ([@R7]). Dyslipidemia in adolescence also predicts CVD risk in adulthood, particularly high LDL-C and non-HDL-C ([@R3]). Both obesity and dyslipidemia have been identified as important treatment targets in childhood and adolescence for the reduction of lifelong CVD risk, and metabolic bariatric surgery (MBS) has been demonstrated to effectively treat severe obesity and improve dyslipidemia in adolescents ([@R3], [@R8]).

Physical activity (PA) also improves lipid levels, reduces CVD risk and supports weight loss maintenance. However, PA participation wanes in adolescence ([@R9], [@R10]). At age 18, daily step counts of 8,000 -- 9,000 steps/day at a moderate cadence of \>87 steps per minute have been reported in adolescents of healthful weight ([@R11], [@R12]). Severe obesity is associated with approximately 50% fewer steps/day, slower cadence and more sedentary time ([@R13], [@R14]). Assessments of PA in adolescents with severe obesity, pre-and post-MBS, are sparse and largely based upon self-report, which has been repeatedly shown to poorly estimate actual PA ([@R15], [@R16]). PA participation and its potential to further improve lipid measures post-MBS have been examined in adults, but not in adolescents ([@R17]).

This evaluation examined the influence of PA on lipid changes in adolescents with severe obesity from baseline to 3 years post-MBS. We hypothesized that objectively measured PA would be positively associated with improvement in lipid measures. Study participants were enrolled in the Teen-LABS study, which collected longitudinal, prospective, observational clinical and laboratory data in adolescents undergoing MBS at five centers in the United States.

METHODS {#S6}
=======

Design {#S7}
------

This analysis was designed to examine associations between objectively measured PA and changes in lipid measures before and after MBS (Roux-en-Y gastric bypass \[RYGB, n=92\] and vertical sleeve gastrectomy \[VSG, n=16\]), in adolescents. PA was defined by daily step counts and cadence (steps per minute). Moderate activity was defined as a cadence \>80 steps per minute, as described by King et al. ([@R18]). The methods used for data collection have been described previously ([@R19]). The original protocol and data and safety monitoring plans were approved by the institutional review board (IRB) at each of the five participating institutions and by a data and safety monitoring board. All participants and/or their legally-authorized representatives provided written informed consent. The analysis plan was also reviewed and approved by the IRB at the University of Colorado, Anschutz Medical Campus.

Participants {#S8}
------------

Adolescents with severe obesity who participated in the Teen-LABS study received MBS (VSG or RYGB) and completed objective measurements of PA were included ([@R19]). More specifically, for inclusion in the analyses, participants had 1) StepWatch™ activity data for a minimum of 3 days (2 weekdays and 1 weekend day), 2) at least 6 hours with at least 10 steps per hour per day of recorded data, 3) data collection at baseline and at least one postoperative time point (6 months, 1 year, 2 years or 3 years), 4) time point-matched laboratory and anthropometric data and 5) no lipid-lowering medication(s). Original, objectively measured Teen-LABS data was used for all analyses. No significant differences were noted in demographics or baseline outcomes between the included and the excluded participant groups.

Outcomes of interest {#S9}
--------------------

The primary outcome of interest was change in lipid measures of cardiovascular risk, primarily non-HDL-C and LDL-C, calculated using the Friedewald equation and secondarily, HDL-C, plasma total cholesterol (TC), and triglycerides (TG). The clinical significance of the changes in lipid measures was also examined as percent resolution of dyslipidemia, defined as a change in individual lipid measures from outside of acceptable range at baseline to acceptable range at 1 and 2 years based upon 2011 guidelines from the National Heart Lung and Blood Institute ([@R20]). Additional secondary outcomes included weight change as iliac waist circumference (IWC) and BMI. Activity trajectory membership was the independent variable of interest and covariates chosen a priori included sex, race, visit and surgical procedure.

Statistical Analysis {#S10}
--------------------

The SAS *PROC TRAJ* procedure was used for latent class modeling to separate participants by categorical activity trajectories using the average step count data for a visit. The optimal model was identified based on the process described by Andruff et al. to select the number of categorical activity trajectories and their respective shape (e.g., linear vs. quadratic) ([@R21]). Based upon this optimal model, two categories were identified that we label "less active" (LA) and "more active" (MA), that were linear and quadratic in shape, respectively. The probability of group trajectory membership for each individual was determined from the individual's trajectory of average step counts across all available time points. The analyses examined lipid and anthropometric outcomes by time periods of clinical relevance including baseline to 1 year as a period of active weight loss and baseline to 2 years and 3 years, as periods of relative weight-loss maintenance.

Descriptive summaries included mean and standard deviation for continuous measures and count and percent of total for discrete measures. Baseline comparisons between activity categories were made using two-sample t-tests for continuous outcomes and two-sample tests of proportions for dichotomous outcomes. Triglyceride values were log-transformed.

Analysis of change in outcomes by trajectory categories used linear regression with generalized estimating equations, assuming an exchangeable working correlation structure to account for the longitudinal, correlated nature of our data to estimate the change from baseline to a measured period of time or visit. Change in lipid outcome from baseline were fit, adjusting for percent change from baseline to a given visit for both IWC and BMI as independent covariates of weight loss in order to examine the impact of general obesity as BMI and central obesity as IWC. The model also potentially included covariates for baseline lipid, sex, surgical procedure type, race/ethnicity (white, non-Hispanic vs. all others), PA trajectory group, study visit indicator, and the interaction between trajectory and visit indicator. To improve interpretability, reduced models were created by iteratively removing sex or race if the adjusted p\>0.1, and the model refit before evaluating significance of the remaining covariate. Additionally, the interaction was removed if the adjusted p\>0.05. Similar models were fit for change in central adiposity measure, but with percent change in the covariate excluded from the model. Graphs were created to illustrate individual and activity category trajectories, plotting average step count over time from baseline to specified visits and changes in the lipid and anthropometric measures of interest over time, as well. SAS v9.4 (SAS Institute Inc., Cary, NC, USA) was used for identifying trajectories and R v3.5.0 (R Foundation for Statistical Computing, Vienna, Austria) was used for all other analyses and figures.([@R22])

RESULTS {#S11}
=======

Participants {#S12}
------------

Of the 242 adolescents enrolled in the Teen-LABS study, 125 provided PA data generated from wearing a StepWatch™ activity monitor. Of the 125 participants with objective PA data, 108 met criteria for inclusion in these analyses, with 14 classified as MA (mean probability of 97.8%) and 94 as LA (mean probability 99.2%). The baseline characteristics of the study participants are presented in [Table 1](#T1){ref-type="table"}. In this analysis of 108 participants, 77% were female, 75% were white, and 11% were Hispanic. The baseline mean (SD) age was 17.0 (1.6) years. The baseline mean (SD) BMI was 54.3 (9.87) kg/m^2^, and mean IWC by horizontal iliac crest measurement was 149.6 (17.3) cm. Baseline mean plasma TC was 161 (31.3) mg/dL, LDL-C 95 (28) mg/dL, non-HDL-C 122 (30.8) mg/dL, logTG was 5 (1), and HDL-C was 39 (9.5) mg/dL. When the cohort was examined by activity trajectory, MA vs. LA, there were no significant differences in baseline lipid values, race/ethnicity, or surgical procedure ([Table 2](#T2){ref-type="table"}).

The MA trajectory average daily step count was \>6,000 average steps at baseline and increased to \>9,000 at 2 years. The LA trajectory was characterized by a stable daily step count of \<4,000 steps per day from baseline to 3 years ([Figure 1](#F1){ref-type="fig"}). Cadence was consistent at all time points, with no participant recording more than 4 minutes of moderate activity cadence per day (\>80 steps/minute) ([Table 3](#T3){ref-type="table"}).

Primary outcome {#S13}
---------------

The MA trajectory was associated with significantly greater absolute decrease in non-HDL-C (−15 mg/dL, 95% CL: (−28, −1), p=0.035), adjusting for baseline non-HDL-C, time, percent change in IWC and procedure ([Table 4](#T4){ref-type="table"}). Similarly, a greater absolute decrease in LDL-C was associated with the MA trajectory, adjusting for baseline LDL-C, time, procedure, and for either percent change in IWC (−15 mg/dL, 95% CI: (−28, −2), p=0.026 or % change in BMI (−13 mg/dL, 95% CI: (−26, 0), p=0.044). In the same models, RYGB surgical procedure was associated with an additional absolute reduction of −19 mg/dL in measured non-HDL-C (95% CI: (−5, −33), p=0.007) and a reduction of −15 mg/dL in calculated LDL-C (95% CI: (−2, −27), p=0.019) over the VSG procedure ([Table 4](#T4){ref-type="table"}). Trajectories illustrating individual and activity trajectory mean longitudinal change in non-HDL-C and LDL-C by procedure are shown in [Figure 2](#F2){ref-type="fig"}.

Secondary outcomes {#S14}
------------------

HDL-C increased in association with both activity trajectories throughout active weight loss, baseline to 1 year, and throughout weight loss maintenance to 3 years, (p\<0.001 for both models) in association with time and percent change in BMI. Female sex was associated with an additional mean absolute HDL-C increase of 3 mg/dL (95% CI: (0, 6), p = 0.05) in the model adjusting for % change in BMI. Non-white race was associated with a mean absolute HDL-C increase of 3.9 mg/dL (95% CI: (0.3, 7.5), p=0.029) or 4.4 mg/dL (95% CI: (0.7, 9.10), p=0.021) after adjusting for % change in IWC or % change in BMI, respectively. Surgical procedure (RGYB vs. VSG) did not appear to influence improvement in HDL-C (p\>0.6 for both models).

Trajectories illustrating individual and activity trajectory mean longitudinal change in HDL-C and TG by procedure are also shown in [Figure 2](#F2){ref-type="fig"}. Improvement in TG was not associated with activity trajectory (p\>0.2 for all models) but was strongly associated with the active weight loss period from baseline to 1 year (p\<0.001 for both models), indicating the predicted additional decrease of 0.22 to 0.25 in log TG value in year 1 was largely influenced by weight loss. The influence of change in BMI on log TG was significant (p=0.041) as indicated by a decrease of 0.01 in log triglyceride value for every 1% decrease in BMI.

Of clinical significance, a greater percentage of elevated measures of non-HDL-C, LDL-C and TG converted to acceptable values in association with the MA trajectory over time compared with the LA trajectory. This was based upon the 2011 Integrated Guidelines ([@R20]) ([Table 5](#T5){ref-type="table"}). Overall, the conversion of elevated lipid measures to acceptable lipid values occurred more often with MA trajectory membership, compared to the LA trajectory membership.

Importantly, the MA trajectory was also associated with an 11% greater reduction in BMI at 3 years compared to the LA trajectory, 95% CI: (−22, −0.2), p=0.046. White, non-Hispanic race was also more likely to experience weight loss with an average 7% greater reduction in BMI, 95% CI: (−11, −4), p\<0.001. (BMI and central adiposity regression tables not shown).

DISCUSSION {#S15}
==========

These results demonstrate that using objectively-measured PA, a relationship between PA and improvement in lipid status beyond weight loss post-MBS in severely obese adolescents was demonstrated. As has previously been reported in adults post-MBS, PA was low ([@R24]), well below the equivalent of recommended 60 minutes of moderate-to-vigorous PA daily in adolescence ([@R23]), or 30 minutes of moderate-to-vigorous PA on at least 5 days of the week for adults, or the typical 8,000--9,000 steps/day at a moderate cadence ([@R11], [@R23]). Additionally, cadence was too low to be considered moderate activity with fewer than 4 high-step-count minutes recorded by any participant. Yet, despite overall low step counts and slow cadence, objectively-measured PA post-MBS was associated with a greater improvement in absolute change in LDL-C, adjusting for baseline lipid value, percent BMI change, and procedure despite overall low step counts. PA was also associated with greater improvement in non-HDL-C, accounting for baseline lipid value, surgical procedure, and either percent BMI change or percent IWC change. Also, membership in the MA trajectory effectively doubled the percentage of participants with resolution of dyslipidemia at 2 years, as indicated by the return to acceptable values of LDL-C, non-HDL-C and TG ([@R20]). In contrast, \<9% of LDL-C, non-HDL-C and TG dyslipidemia resolved from baseline to 2 years in association with the LA trajectory. Importantly, by 36 months post-MBS, these results demonstrate a normalization of dyslipidemia in participants falling within the MA trajectory category. Of particular interest, our study did not find that activity was associated with longitudinal increases in HDL-C or clinical remission of HDL-C dyslipidemia, as has been previously reported in adults ([@R25]). We found that HDL-C increased from baseline to 2 years post-MBS in association with time, suggesting the improvement in HDL-C at each time-point was related to the impact of MBS, rather than PA. Additionally, the association of increased PA with greater weight loss and improved weight loss maintenance post-MBS suggests the possibility of an expected causal relationship. Although supported by previously published reports in adults ([@R24]) this cannot be confirmed without future studies designed to measure these effects in adolescents. The MA trajectory was associated with an 11% greater decrease in BMI at 3 years, extending well beyond the period of active weight loss, from baseline to 12 months. The unexpected finding that RYGB may influence a larger reduction in non-HDL-C and LDL-C over VSG is worthy of further examination and confirmation as the VSG participants were few. PA-associated improvements in lipid outcomes persisted even when adjusted for percent change in BMI.

An augmented activity-associated decrease in CVD-related lipid values and greater long-term weight loss post-MBS in adolescents likely predict better long-term outcomes and improved cardio-metabolic status. This is important because CVD is strongly associated with dyslipidemia and BMI ([@R7], [@R26]). Improved lipid measures and clinical remission of dyslipidemia in association with weight loss post-MBS has previously been reported in adults and adolescents ([@R8], [@R25], [@R27]--[@R29]). Although percent BMI change was the primary contributor to improvements in LDL-C, non-HDL-C, HDL-C and TG post-MBS, physical activity was associated with further decrease in CVD-related lipids, LDL-C and non-HDL-C. Likewise, clinical dyslipidemia has previously been reported to resolve in 66% of adolescents post-MBS ([@R30]). In this analysis, more activity was associated with almost complete resolution of dyslipidemia. While both physical activity and MBS have been reported to increase HDL-C ([@R31]), our study found that physical activity was not associated with an increase in HDL-C. It may be that the low step counts and slow cadence of the population were insufficient to increase HDL-C. This is worthy of future exploration in adolescents with severe obesity.

PA has also been previously shown to support weight loss and weight loss maintenance resulting from both lifestyle modification and MBS in adults, however self-reported PA did not distinguish maintainers from those who failed to maintain weight loss in adolescents, post-MBS ([@R15], [@R32]). By examining objectively-measured activity data, our study demonstrated that more objectively-measured physical activity was associated with greater weight loss in the weight maintenance period from 1 year to 3 years, well beyond the period of active weight loss at year 1.

These results are unique and highlight the value of PA to modify cardio-metabolic risk and improve individual long-term outcomes as an adjunct therapy to MBS in adolescents with severe obesity. These study results are strengthened by the longitudinal study design, the use of an objective PA measure and the analysis of individual longitudinal activity trajectories rather than median or group means, accounting for sex, race, procedure, baseline data, and percent change in BMI or IWC. There are limitations to be considered as well, including limited PA participation among the adolescent-with-severe-obesity population, fewer VSG participants, limited StepWatch™ data available from the Teen-LABS participants, and limitation of recoding steps and cadence with StepWatch™. Participant self-selection may have influenced the participation with step data collection and continued participation over time. Also, individual dietary intake was not available in the Teen-LABS data set, although pre- and post-MBS dietary instructions were consistent for all of the participants.

In summary, in adolescents with severe obesity, PA appears to further reduce lipid-related-CVD risk and support long-term weight loss maintenance, post-MBS. As such, PA support should be included as an integral part of the chronic care plan for all adolescents undergoing MBS. Further research is needed to determine best practices and strategies to modify PA behavior among adolescents with severe obesity. Additionally, a better understanding of the frequency, intensity and duration of PA needed pre- and post-MBS is needed to modify specific lipid and weight maintenance outcomes longitudinally in adolescents and adults. Additional study is needed to confirm the potential influence of surgical procedure type in the reduction of CVD-related LDL-C and non-HDL-C and weight maintenance.
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###### 

Baseline summary table for all participants with baseline and at least one 3-day StepWatch™ record

As mean (SD) or N (%).

  -----------------------------------------------------------------------------------
  Covariate                                Overall\     More Active\   Less Active\
                                           (N=108)      (N=14)         (N=94)
  ---------------------------------------- ------------ -------------- --------------
  Female                                   83 (76.9%)   11 (78.6%)     72 (76.6%)

  Hispanic/Latino                          12 (11.1%)   0 (0.0%)       12 (12.8%)

  Race:                                                                

   White or Caucasian                      81 (75.0%)   11 (78.6%)     70 (74.5%)

   Black or African American               21 (19.4%)   2 (14.3%)      19 (20.2%)

   Asian                                   1 (0.9%)     0 (0.0%)       1 (1.1%)

   American Indian or Alaskan Native       1 (0.9%)     0 (0.0%)       1 (1.1%)

   More Than One Race                      4 (3.7%)     1 (7.1%)       3 (3.2%)

  Surgery Type RYB (vs. GS)                92 (85.2%)   13 (92.9%)     79 (84.0%)

  Number of Visits with Valid Step Data:                               

   1                                       38 (35.2%)   8 (57.1%)      30 (31.9%)

   2                                       31 (28.7%)   1 (7.1%)       30 (31.9%)

   3                                       23 (21.3%)   4 (28.6%)      19 (20.2%)

   4                                       13 (12.0%)   1 (7.1%)       12 (12.8%)

   5                                       3 (2.8%)     0 (0.0%)       3 (3.2%)
  -----------------------------------------------------------------------------------

###### 

Baseline comparison of Less Active and More Active trajectories using two-sample t-tests or tests of proportions for p-values

  Covariate                   More Active Mean (SD)   Less Active Mean (SD)   Difference \[More-Less\] (95% Cl)   p-value
  --------------------------- ----------------------- ----------------------- ----------------------------------- ---------
  HDL-C (mg/dL)               44 (11)                 39 (9)                  5 (−1,12.0)                         0.104
  non-HDL-C(mg/dL)            123 (31)                121 (31)                2 (−17,21)                          0.836
  LDL-C ( mg/dL)              102(36)                 94 (27)                 8 (−14,29)                          0.448
  log(TG)                     5 (0)                   5 (1)                   0 (−0.5,0.1)                        0.117
  BMI (kg/m^2^)               51 (8)                  55 (10)                 −4 (−9,1)                           0.111
  IWC(cm)                     146 (15)                150 (17)                −3(−13,6)                           0.459
  Body Fat (%)                54 (6)                  54 (4)                  0.9 (−3,4)                          0.611
  Age (yrs.)                  17 (1)                  17 (2)                  0 (−1,1)                            0.458
  Total Cholesterol (mg/dL)   167 (34)                160 (31)                7 (−13, 27)                         0.458

CI -- confidence interval (95% confidence that the true population value will be located between these limits)

###### 

Summaries of average (SD) daily step count across time by sex

             *All Participants*   *Boys*          *Girls*                        
  ---------- -------------------- --------------- --------- --------------- ---- ---------------
  Baseline   66                   3,899 (1,818)   10        4,035 (1,615)   56   3,875 (1,865)
  6 Month    68                   4,186 (2,236)   17        4,238 (1,953)   51   4,168 (2,340)
  12 Month   53                   4,405 (1,820)   14        4,745 (1,851)   39   4,283 (1,818)
  24 Month   35                   4,560 (2,291)   11        4,449 (1,689)   24   4,611 (2,552)
  36 Month   14                   4,963 (3,473)   5         6,657 (4,387)   9    4,023 (2,681)

###### 

Absolute change in lipid outcome from baseline regression output with percent change in IWC or BMI as the adiposity measure (%Ad)

                                      Iliac Waist Circumference (IWC)   Body Mass Index (BMI)                              
  ----------------------------------- --------------------------------- ----------------------- -------------------------- -------------
  **Outcome: log(TG)**                **Coefficient (95% Cl)**          **p-value**             **Coefficient (95% Cl)**   **p-value**
  Intercept                           1.91 (1.22, 2.59)                 \<0.001                 2.09 (1.41, 2.78)          \<0.001
  Baseline log(TG)                    −0.48 (−0.62, −0.34)              \<0.001                 −0.50 (−0.64, −0.35)       \<0.001
  White, non-Hispanic (vs. "Other")   0.16 (0.04,0.27)                  0.007                   0.20 (0.08, 0.32)          \<0.001
  %Ad Change from Baseline            0.01 (0.00, 0.01)                 0.255                   0.01 (0.00, 0.02)          0.041
  MA (vs. LA)                         −0.10 (−0.27, 0.06)               0.224                   −0.09 (−0.25, 0.07)        0.282
  Baseline to 1 Year                  −0.25 (−0.34, −0.16)              \<0.001                 −0.22 (−0.31, −0.14)       \<0.001
  Baseline to 2 Years                 −0.07 (−0.21, 0.07)               0.327                   −0.09 (−0.22, 0.05)        0.222
  Baseline to 3 Years                 −0.12 (−0.37, 0.13)               0.343                   −0.15 (−0.39, 0.10)        0.237
  VSG Procedure (vs. RYGB)            0.11 (−0.08, 0.30)                0.266                   0.09 (−0.10, 0.29)         0.337
  **Outcome: HDL-C**                  **Coefficient (95% Cl)**          **p-value**             **Coefficient (95% Cl)**   **p-value**
  Intercept                           16.51 (5.88, 27.14)               0.002                   12.55 (3.01, 22.09)        0.010
  Baseline HDL                        −0.28 (−0.54, −0.03)              0.026                   −0.23 (−0.47, 0.01)        0.056
  White, non-Hispanic(vs. "Other")    −3.93 (−7.54, −0.31)              0.033                   −4.37 (−8.10, −0.65)       0.021
  Male                                −3.14 (−6.45, 0.16)               0.062                   −3.21 (−6.43, 0.01)        0.050
  %Ad Change from Baseline            −0.17 (−0.39, 0.06)               0.152                   −0.22 (−0.38, −0.06)       0.009
  MA (vs. LA)                         1.51 (−3.63, 6.64)                0.565                   0.39 (−4.71, 5.49)         0.881
  Baseline to 1 Year                  6.17 (4.24, 8.11)                 \<0.001                 5.10 (2.97,7.22)           \<0.001
  Baseline to 2 Years                 9.83 (7.06, 12.60)                \<0.001                 9.45 (6.64, 12.25)         \<0.001
  Baseline to 3 Years                 7.31 (3.53, 11.08)                \<0.001                 7.34 (3.67, 11.01)         \<0.001
  VSG Procedure (vs. RYGB)            −0.64 (−4.84, 3.56)               0.765                   −1.00 (−5.26, 3.26)        0.645
  **Outcome: non-HDL-C**              **Coefficient (95% Cl)**          **p-value**             **Coefficient (95% Cl)**   **p-value**
  Intercept                           44.39 (22.52, 66.26)              \<0.001                 51.78 (29.42, 74.13)       \<0.001
  Baseline non-HDL                    −0.43 (−0.57, −0.29)              \<0.001                 −0.42 (−0.56, −0.28)       \<0.001
  %Ad Change from Baseline            0.52 (−0.08, 1.12)                0.092                   0.69 (0.21, 1.18)          0.005
  MA (vs. LA)                         −14.62 (−28.18, −1.06)            0.035                   −12.78 (−26.07, 0.51)      0.059
  Baseline to 1 Year                  −7.76 (−12.78, −2.75)             0.002                   −6.19 (−11.19, −1.18)      0.015
  Baseline to 2 Years                 −4.02 (−12.01, 3.96)              0.323                   −3.44 (−10.77, 3.89)       0.358
  Baseline to 3 Years                 −3.45 (−17.05, 10.15)             0.619                   −3.98 (−17.90, 9.95)       0.576
  VSG Procedure (vs. RYGB)            19.36 (5.30, 33.42)               0.007                   19.33 (5.13, 33.54)        0.008
  **Outcome: LDL-C**                  **Coefficient (95% Cl)**          **p-value**             **Coefficient (95% Cl)**   **p-value**
  Intercept                           41.37 (23.48, 59.26)              \<0.001                 47.24 (29.21, 65.26)       \<0.001
  Baseline LDL                        −0.43 (−0.59, −0.27)              \<0.001                 −0.42 (−0.58, −0.26)       \<0.001
  %Ad Change from Baseline            0.47 (−0.01, 0.94)                0.053                   0.59 (0.21, 0.97)          0.002
  MA (vs. LA)                         −14.83 (−27.88, −1.78)            0.026                   −13.26 (−26.14, −0.38)     0.044
  Baseline to 1 Year                  −3.32 (−8.18, 1.53)               0.180                   −2.04 (−6.80, 2.72)        0.401
  Baseline to 2 Years                 −2.46 (−9.30, 4.38)               0.481                   −1.34 (−7.69, 5.00)        0.679
  Baseline to 3 Years                 −3.76 (−14.64, 7.12)              0.498                   −4.10 (−15.40, 7.19)       0.476
  VSG Procedure (vs. RYGB)            15.12 (2.39, 27.86)               0.020                   15.27 (2.48, 28.05)        0.019

###### 

Counts (%) of those with acceptable lipid status at baseline, year 1, and year 2 by activity trajectory

  --------------- ------------------------ ------------------------
  **TG**          Less Active Trajectory   More Active Trajectory
  Baseline        27/94 (28.7%)            5/14 (35.7%)
  Year 1          49/61 (80.3%)            9/9 (100%)
  Year 2          27/37 (70.3%)            5/6 (83.3%)
  **HDL-C**       Less Active Trajectory   More Active Trajectory
  Baseline        20/94 (21.3%)            4/14 (28.6%)
  Year 1          37/61 (60.7%)            6/9 (66.7%)
  Year 2          25/37 (67.6%)            4/6 (66.7%)
  **non-HDL-C**   Less Active Trajectory   More Active Trajectory
  Baseline        52/94 (55.3%)            6/14 (42.9%)
  Year 1          50/61 (82%)              8/9 (88.9%)
  Year 2          27/37 (73%)              5/6 (83.3%)
  **LDL-C**       Less Active Trajectory   More Active Trajectory
  Baseline        70/94 (74.5%)            7/14 (50%)
  Year 1          53/61 (86.9%)            8/9 (88.9%)
  Year 2          31/37 (83.8%)            6/6 (100%)
  --------------- ------------------------ ------------------------

Acceptable values defined as: HDL-C\>45mg/dL, LDL-C\<110 mg/dL, non-HDL-C\<120 mg/dL, TG\<90 mg/dL.([@R20])

###### STUDY IMPORTANCE:

What is already known about this subject? {#S17}
=========================================

-   Dyslipidemia and obesity in adolescence track into adulthood and greatly increase cardiovascular disease (CVD) risk.

-   Dyslipidemia remits in the majority of adolescents with severe obesity, post-metabolic bariatric surgery.

-   Metabolic bariatric surgery effectively treats severe obesity in adolescents, yet weight loss and weight loss maintenance remain variable.

-   Physical activity improves lipid levels, reduces CVD risk, improves weight loss and supports weight loss maintenance.

What does this study add? {#S18}
=========================

-   Greater decreases in CVD-related lipids, specifically LDL-C and non-HDL-C, are associated with more physical activity post-metabolic bariatric surgery in adolescents with severe obesity.

-   LDL-C and non-LDL-C dyslipidemia remission rates increase in association with more physical activity in adolescents with severe obesity, post-metabolic bariatric surgery.

-   Weight loss maintenance, indicated by an 11% greater decrease in BMI at 3 years, was associated with more physical activity in adolescents with severe obesity, post-metabolic bariatric surgery.
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